Can hydrogen gas help treat pulmonary fibrosis?

This study shows hydrogen inhalation significantly reduced lung scarring in animal models of pulmonary fibrosis. The treatment worked by reducing oxidative stress and blocking harmful signaling pathways that cause scarring.

How does hydrogen inhalation work against lung scarring?

Hydrogen gas reduces harmful reactive oxygen species, blocks TGF-β1 protein that promotes scarring, and prevents healthy lung cells from transforming into scar tissue. It also decreases inflammation and collagen deposits in the lungs.

Is hydrogen inhalation therapy safe for lung patients?

Hydrogen gas is generally considered safe and non-toxic. However, this study was conducted in animals, so human safety and effectiveness still need to be confirmed through clinical trials.

What is epithelial-mesenchymal transition in lung disease?

EMT is when healthy lung cells transform into scar-forming cells, contributing to pulmonary fibrosis. This study found hydrogen therapy helps prevent this harmful transformation.

Could hydrogen therapy replace current pulmonary fibrosis treatments?

The researchers suggest hydrogen inhalation could work as an adjuvant therapy alongside existing treatments. More research is needed to determine its role in comprehensive treatment plans for human patients.

Hydrogen Gas Reduces Lung Scarring in Animal Study

Authors: Li Gao, Dingyuan Jiang, Jing Geng, Run Dong, Huaping Dai
Journal: Experimental Physiology
Year: 2019
DOI: 10.1113/EP088028
Study Type: Rat
Outcome: Positive
Peer Reviewed: Yes
Country: China
Health Condition: Pulmonary Fibrosis
Body System: Respiratory

TL;DR

Breathing in hydrogen gas can reduce lung scarring and damage caused by a drug called bleomycin in rats.

Key Finding

Hydrogen gas inhalation reduced bleomycin-induced lung scarring in rats by lowering oxidative stress and blocking key proteins involved in the fibrosis process.

Summary

Researchers tested whether inhaling hydrogen gas could help treat pulmonary fibrosis (lung scarring) in rats. They found that hydrogen inhalation reduced lung damage caused by bleomycin (a chemotherapy drug) by decreasing harmful molecules called free radicals, blocking a protein called TGF-β1 that promotes scarring, and preventing lung cells from transforming into scar-forming cells.

Practical Takeaway

This rat study suggests hydrogen inhalation may have potential as a treatment for pulmonary fibrosis, but it is very early-stage research. Human clinical trials would be needed to determine whether these effects occur in people and whether hydrogen could be a safe and effective therapy for lung disease.

Abstract

New findings: • What is the central question of this study? The aim was to explore the effects and underlying mechanisms of H2 on bleomycin (BLM)-induced pulmonary fibrosis. • What are the main findings and its importance? Our results indicate that, in BLM-induced pulmonary fibrosis, H2 inhalation could attenuate oxidative stress and reversed the formation of pulmonary EMT process by reducing ROS production and inhibiting the expression of TGF-β1, α-SMA and collagen I to improve fibrotic injury and exert anti-fibrogenic effects. Thus, H2 inhalation represents promising therapeutic potential as a useful adjuvant treatment for patients with idiopathic pulmonary fibrosis that deserves further study and evaluation. Abstract: Background Hydrogen (H2 ) can protect against tissue damage. The effect of H2 inhalation therapy on the pathogenesis of pulmonary fibrosis remains unknown. This study was to explore the effects and underlying mechanisms of H2 inhalation on bleomycin (BLM)-induced pulmonary fibrosis. Material and Methods Pulmonary fibrosis rat models were established by BLM. Rats were randomly divided into the control and H2 inhalation groups. The H&E and Mason's staining were performed to evaluate pulmonary fibrosis injury, inflammatory cell infiltration, structural disorder and collagen deposition. qRT-PCR and western blot assays were used to determine the expression of TNF-α, TGF-β1, α-SMA, E-cadherin, N-cadherin, vimentin, VEGF and collagen type I at both mRNA and protein levels. The contents of ROS, TGF-β1, TNF-α, MDA and hydroxyproline were determined by biochemical test kits or ELISA kits. Results BLM-stimulated rats exhibited typical symptoms of pulmonary fibrosis which featured as: increased collagen deposition, alveolitis, fibrosis and the parenchymal structural disorder in the lung. However, BLM-induced oxidative stress could be attenuated by H2 inhalation therapy through reducing the contents of ROS, MDA and hydroxyproline, enhancing the activity of glutathione peroxidase and decreasing the expression of TGF-β1 and TNF-α. In addition, H2 inhalation also inhibited BLM-induced epithelial-mesenchymal transitions (EMT) by inhibiting TGF-β1 to increase the expression level of epithelial cell marker E-cadherin while decrease the expression level of mesenchymal cell marker vimentin in a time-dependent manner. In addition, H2 inhalation down-regulated α-SMA expression and suppressed collagen I generation to exert anti-fibrogenic effects. Conclusions H2 inhalation therapy attenuates BLM-induced pulmonary fibrosis by inhibiting TGF-β1 and relevant oxidative stress and EMT. This article is protected by copyright. All rights reserved.